GlassScriptPhysician profile
Karan Desai
NPI 1861781239
$39,264.25
in general payments reported to CMS, 2019-2025
28 companies · $17K in 2025
The $17K reported for 2025 was more than what 98% of Surgery of The Hand (Plastic Surgery) providers received nationally (typical 2025 total: $312).
See the full distribution for Surgery of the Hand (Plastic Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $2,862 · 2021: $1,904 · 2022: $3,188 · 2023: $6,997 · 2024: $6,681 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,933 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,400 · Food and Beverage: $6,180 · Consulting Fee: $5,000 · Honoraria: $3,000 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,933.24 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,400.00 |
| Food and Beverage | $6,180.47 |
| Consulting Fee | $5,000.00 |
| Honoraria | $3,000.00 |
| Education | $187.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Trimed, INC. | $23,350.11 | 2020-2025 | |
| Checkpoint Surgical, INC | $8,028.34 | 2020-2025 | Checkpoint Stimulators |
| Arthrex, INC. | $3,069.16 | 2020-2022 | |
| Reel Surgical, INC. | $2,361.19 | 2020-2025 | |
| Axogen | $574.54 | 2019-2025 | |
| Integra Lifesciences Corporation | $483.69 | 2019-2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Polynovo North America LLC | $173.38 | 2025 | Novosorb Btm |
| Tei Biosciences INC | $169.71 | 2019 | |
| Endo Pharmaceuticals INC. | $128.39 | 2019-2021 | |
| Smith+Nephew, INC. | $114.20 | 2022-2025 | Pico 14, Evos |
| Stryker Corporation | $112.48 | 2019-2024 | Blueprint Patient Specific Instrumentation |
| Renerve LTD | $107.14 | 2025 | Nervalign Nerve Cuff |
| Zimmer Biomet Holdings, INC. | $84.49 | 2019 | |
| Kerecis Limited | $66.06 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Linvatec Corporation | $65.19 | 2024 | Biobrace 23mm |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $52.11 | 2020-2022 | |
| Trice Medical, INC. | $50.00 | 2020 | |
| Acumed LLC | $48.16 | 2022 | |
| US Implant Solutions, LLC | $35.33 | 2023 | |
| Mentor Worldwide LLC | $35.00 | 2019 | |
| Medartis INC. | $32.47 | 2022 | |
| Acera Surgical, INC. | $28.58 | 2025 | Restrata Wound Matrix |
| Acell, INC. | $22.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.13 | 2021 | |
| Mimedx Group, INC. | $14.98 | 2025 | |
| Bioventus LLC | $14.92 | 2024 | Exogen Ultrasound Bone Healing System |
| Orthocell LTD | $13.62 | 2025 | Remplir |
| Sonex Health, INC. | $10.91 | 2023 | Sx-One Microknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karan Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.